CAMBRIDGE, Mass., March 10, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Tuesday, March 16th, 2021, at 4:30 p.m. ET.
About KSQ Therapeutics
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies. For more information, please visit the company’s website at www.ksqtx.com and follow @ksq_tx on Twitter.
Media Contact:
Cory Tromblee
Tel: 617-571-7220
cory@scientpr.com
© 2024 KSQ Therapeutics, Inc. All rights reserved.